CooperCompanies announced it has closed the acquisition of select Cook Medical assets focused primarily on the obstetrics, doppler monitoring, and gynecology surgery markets. The purchase price was $300 million with $200 million paid at closing and the remaining $100 million to be paid in two $50 million annual installments.
The assets being acquired are primarily minimally invasive medical devices including the Bakri Postpartum Balloon, Cook’s Cervical Ripening Balloon, the Doppler Blood Flow Monitor portfolio, and select surgical products. The acquired assets generated approximately $56 million in trailing twelve-months revenue as of September 30, 2023.
As part of Cooper’s fiscal year 2024, revenues from this transaction are expected to grow 5-7% year-over-year in constant currency. Excluding one-time charges and deal-related amortization, the transaction is expected to be accretive to non-GAAP gross and operating margins and accretive to non-GAAP earnings per share by approximately $0.20.
Cooper will report these assets as part of its Office and Surgical category within the CooperSurgical business beginning in its fiscal first quarter of 2024. This transaction does not include any of the fertility products contemplated in the original deal announced on February 7, 2022.
